Every number in the Union Health Ministry’s announcement on September 11, 2026 deserves to be read slowly. Eighty lakh doses of the Human Papillomavirus vaccine had been administered in a little over six months, and twenty-two lakh of those doses went to adolescent girls in Uttar Pradesh alone. Gujarat, Uttar Pradesh, Madhya Pradesh and Mizoram reached one hundred per cent of their identified target populations; Bihar, Andhra Pradesh and Assam crossed ninety per cent; Karnataka passed eighty-five; and Chhattisgarh, Sikkim, Kerala, Telangana and Odisha crossed sixty. But the true scale of the achievement is not in the aggregate. Each unit in that total is a fourteen-year-old girl who, in all statistical likelihood, will never develop the cancer that currently kills an Indian woman roughly every seven minutes. The vaccine is offered free, as a single dose, to girls aged fourteen, at government health facilities, and only after a parent or guardian has given informed consent. The annual cohort of fourteen-year-olds in India is estimated at about 1.2 crore, according to Registrar General projections for 2021, so the campaign has reached roughly a third of this year’s eligible girls, not through a parallel apparatus built for a photo opportunity, but through the ordinary capillaries of the public system: Ayushman Arogya Mandirs, primary and community health centres, sub-district and district hospitals, and government medical colleges. This is the quiet, unglamorous work of public health, and the state-level breakdown makes it legible. Uttar Pradesh, once treated as shorthand for administrative collapse, has done the heaviest lifting in absolute terms, carrying the single largest share of a national preventive health drive.
To understand why this is a political fact and not merely a logistical one, you have to return to mid-2009. Seattle-based PATH, working with the Indian Council of Medical Research and the governments of Andhra Pradesh and Gujarat, and funded by the Bill and Melinda Gates Foundation, ran what it called a demonstration project. Roughly 23,000 girls between ten and fourteen received donated HPV vaccine doses in Khammam and Vadodara. Seven girls died. The Health Ministry suspended the project in 2010, and a 2013 parliamentary standing committee tabled a scathing report, concluding that a clinical trial had been conducted under the softer label of observation, with consent procedures that could not withstand scrutiny. Honesty requires two things to be said together. No causal link was ever established between the vaccine and those seven deaths; the reported causes were unrelated. But the regulatory conduct was indefensible, and the Ministry’s own 2014 response to Parliament conceded collective failure three times over. India then did what institutions do when they are embarrassed: it went quiet. The silence lasted sixteen years, and a legitimate grievance about research ethics curdled in that vacuum into a general belief that the vaccine itself was the danger. It is a fair emblem of the distance travelled that Jagat Prakash Nadda, who sat on the committee that delivered the 2013 indictment, now presides over the Ministry running the national rollout.
The campaign was launched into hostile weather. Within hours of Prime Minister Narendra Modi’s launch in Ajmer on February 28, social media carried the familiar catalogue of claims: that the vaccine causes infertility, that it triggers neurological and autoimmune disease, that it encourages early sexual activity, that it is a foreign philanthropist experiment on Indian daughters. What blunted the rumour was not a counter-campaign on the same platforms, though radio, posters and digital outreach were duly deployed. It was that the person asking a mother for consent was usually a frontline health worker she already knew, standing in a health centre she had used before. Misinformation travels through screens; trust travels through faces. India’s frontline network, built over decades and mobilised here through district-level health teams, remains its most underrated line of defence against an infodemic. Doctors also stepped forward. On February 26, the gynaecologist Dr Poornima published a widely shared rebuttal pointing out that India records about 1,27,526 new cervical cancer cases a year, and that the three HPV vaccines in Indian use, Cervavac from the Serum Institute, Gardasil from Merck and Cervarix from GSK, are owned by none of the philanthropists named in conspiracy theories. The Mumbai surgeon Amit Thadhani set the efficacy range at 93 to 100 per cent against targeted HPV types and noted that litigation against the vaccine had largely collapsed in foreign courts. Yet hesitancy remains stubborn, and it is not a rural or illiterate phenomenon. At a free vaccination camp during a government expo at Bharat Mandapam in July, only thirty-four of two hundred eligible girls accepted the shot, and doctors reported that roughly every second parent asked whether the vaccine would affect their daughter’s future fertility. Peer-reviewed content analysis of HPV conversation on X has found that close to a quarter of posts on the subject carry misinformation, and that those posts attract higher engagement than accurate ones.
The Indian version of vaccine scepticism has a distinctive feature: it did not stay on the timeline. The public interest litigation heard by the Delhi High Court on July 29 was filed by gynaecologist Dr Sujata Mittal along with Jitendra Chouksey, the fitness entrepreneur behind the FITTR platform, who had already told a large social media following that he was disinclined to recommend the vaccine to his own family. Their plea questioned the data, the efficacy and the necessity of the programme, argued that school-based sessions and enrolment targets for ASHA workers amounted to pressure on young girls, and cited a fourteen-year-old from Tamil Nadu said to have developed severe neurological symptoms after vaccination in March 2026. That is the modern pipeline in full: a claim is made to an audience of millions, the audience treats reach as credentials, and the claim is then carried into a constitutional court as a grievance requiring judicial remedy. Nothing about it is illegal; everything about it is a test of whether the state can answer speed with evidence. A bench of Chief Justice Devendra Kumar Upadhyaya and Justice Tejas Karia declined to stay the drive, recording the government’s submission that of roughly fifty-five lakh doses administered by then, about 120 recipients had reported nothing worse than nausea or headache. The court did not hand the Centre a clean chit; it insisted that protocol be followed, sought affidavits from the Centre, ICMR, CDSCO and the National Immunization Technical Advisory Group, and listed the matter for October 29. But it refused to halt a preventive programme on the strength of contested anecdote. Six weeks later the Supreme Court was blunter. On September 10, a bench of Chief Justice Surya Kant with Justices Joymalya Bagchi and V Mohana heard a petition from the Universal Health Organisation, which, while disclaiming any anti-vaccine intent, again raised the fertility claim alongside demands on adverse-event monitoring and injury compensation. The bench signalled at the outset that it would not entertain the matter, warned that a public health programme should not be derailed by assertions unsupported by adequate research, and indicated it would record strong observations if the plea were pressed; later the petitioner withdrew. The contrast with Pakistan is instructive: its first HPV campaign, launched in September 2025, aimed at eleven million girls and finished with roughly half that number vaccinated, as health workers had doors shut on them, schools closed for days, families concealed their daughters’ ages, and a prominent political-religious figure told a rally that the nation’s daughters were being made infertile. The difference between that outcome and India’s eighty lakh is not a difference in the quality of the rumour; it is a difference in the quality of the state that met it.
The design of the Indian campaign is itself an argument, and a quietly sophisticated one. Vaccination is voluntary, which answers the coercion charge. Parental consent is mandatory, which answers the charge that the state is acting over the heads of families. Every session is conducted under the supervision of a trained medical officer, and every site is linked to a round-the-clock facility for the assessment and management of rare Adverse Events Following Immunisation, which answers, structurally, the memory of 2009. The programme did not ask the country to forget the last time; it built the safeguards whose absence caused the last time. There is also the weight of global evidence. More than 500 million HPV vaccine doses have been administered worldwide since 2006, making these among the most extensively studied vaccines in existence. India has joined over 160 countries that include HPV vaccination in their national immunisation schedules, and more than ninety are using the single-dose regimen that improves coverage, affordability and programme efficiency in one stroke. The case for urgency rests on a figure that ought to be better known. According to GLOBOCAN 2022 data cited by the government, cervical cancer is the second most common cancer among Indian women, with more than 1.2 lakh new cases and close to 80,000 deaths annually, the highest death toll of any country and almost a quarter of the world’s total. Persistent infection with high-risk HPV types, chiefly 16 and 18, accounts for nearly all of it. A new case is diagnosed roughly every four minutes. Globally, 87 per cent of upper-middle-income countries, 78 per cent of lower-middle-income countries and 54 per cent of low-income countries have adopted HPV vaccination in their national programmes. India, the world’s largest vaccine producer, supplying close to sixty per cent of global vaccine volumes, was for sixteen years absent from that list. That anomaly has now closed.
What remains is the last mile, and the last mile is always the steepest. Eighty lakh doses against an annual cohort of about 1.2 crore means roughly a third of this year’s eligible girls are still waiting. The remaining gap is likely to be concentrated in two very different places: out-of-school girls in districts with weak frontline penetration, and well-off urban households that have decided, on the strength of a forwarded video, that they know better. These require opposite instruments: more health workers for the first, more credible doctors speaking in regional languages for the second. But the deeper meaning of what has already been accomplished should not be lost. Charaka defined the purpose of medicine as the preservation of health in the healthy before the alleviation of disease in the sick. By that standard, a single free dose given to a fourteen-year-old in a Dindori hamlet or a Mizoram village, identical to the one a private clinic in South Delhi charges for, is not merely a health intervention. It is Antyodaya rendered in a syringe: the last girl first, protected decades before the risk arrives, by a system that no longer asks what her family can pay. Swastha Nari, the vision of a healthy woman, is not a slogan here; it is a sequence of appointments kept, consent forms signed, needles administered, and futures altered. The misinformation has not stopped and will not. But eighty lakh Indian families have now weighed a rumour against a doctor and chosen the doctor. That delivery, without compulsion and repeated eight million times, is the most persuasive public health argument India has made in a decade.